Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded by Zacks Investment Research to Hold

Cyclacel Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Cyclacel Pharmaceuticals Upgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded by Zacks Investment Research to Hold